Since we showed that HP1-deficiency impaired homologous recombination repair and rendered BRCAness phenotype in breast cancer cells [17], we confirmed the cytotoxicity of PARP inhibitor for HP1-deficient breast cancer cells (Fig. 4). This evidence concerns the gene PARP1 and breast cancer.